Intraperitoneal immunotherapy of epithelial ovarian carcinoma with Corynebacterium parvum

Berek, Jonathan S.; Knapp, Robert C.; Hacker, Neville F.; Lichtenstein, Alan; Jung, Tyler; Spina, Celsa A.; Obrist, R.; Griffiths, C. Thomas; Berkowitz, Ross S.; Parker, Leroy M.; Zighelboim, Jacob; Bast, Robert C.

doi:10.1016/0002-9378(85)90548-4

Cited by 39 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Both natural killer cells and antibody-dependent cell-mediated cytotoxicity in the peritoneal cavity of responders were shown to be augmented. The investigators feel that regional immunotherapy may prove useful in conjunction with other modalities in the treatment of patients with minimal residual ovarian cancer [8]. An important antigenic determinant CA125, has proven useful in the monitoring of disease progression or regression and correlated with clinical findings in 94% of cases studied; this test may prove useful for monitoring ovarian cancer patients in several current trials testing new single agents as chemotherapy candidates [6].…”

Section: Ovarian Cancermentioning

confidence: 97%

Immunotherapy trials: Current status and future directions with special emphasis on biologic drugs

Hollinshead

1986

Springer Semin Immunopathol

View full text Add to dashboard Cite

Section: Ovarian Cancermentioning

confidence: 97%

Immunotherapy trials: Current status and future directions with special emphasis on biologic drugs

Hollinshead

1986

Springer Semin Immunopathol

View full text Add to dashboard Cite

“…Intravesical BCG is clearly a safe and effective therapy for superficial bladder cancer [49]. Furthermore, intraperitoneal Corynebacterium parvum appears to have produced responses in patients with ovarian cancer, but this therapy led to severe intraperitoneal fibrosis [50]. Of particular note is an adjuvant study comparing conventional therapy (surgery with or without radiation therapy) to the same therapy plus polyadenylic-polyuridylic acid (poly AU), a double-stranded synthetic RNA molecule, in patients with node-positive breast cancer [51].…”

Section: Biological Response Modifiersmentioning

confidence: 99%

Biological response modifiers in the management of patients with breast cancer

Longo

Hartmann

1990

Breast Cancer Res Tr

View full text Add to dashboard Cite

Despite impressive progress in understanding the biology of breast cancer, mechanisms of host defense, and the pathophysiology of the metastatic process, this burgeoning fact bank has made little impact on the management of patients with breast cancer. There are many interesting ideas for improved diagnosis and therapy in various stages of development, but few have actually translated into improved survival of patients with breast cancer. Potentially useful biological agents include cytokines, monoclonal antibodies, immunotoxins, vaccines, and adoptive cellular therapies. Therapies targetting growth factor receptors and the cellular machinery required for metastasis may become useful, especially when used in combination with other cytotoxic agents. Colony-stimulating factors may allow a test of the hypothesis that augmented dose-intensity of cytotoxic chemotherapy will cure more patients. Though we are not yet sure precisely how to use all of these new tools, there can be little doubt that their application will make a significant impact on the management of patients with breast cancer and other malignancies in the next decade.

show abstract

Biologic therapy for the treatment of malignant common epithelial tumors of the ovary

Hamilton¹,

Ozols²,

Longo³

1987

Cancer

View full text Add to dashboard Cite

There are a number of strategies to the treatment of gynecologic tumors that involve the use of biologic agents. Biologic agents may be immunologic in nature and act directly on the tumor or to boost an immune response to the tumor, or they may be nonimmune in nature and directly affect the tumor or a physiologic process on which the tumor depends. Although the potential for these agents in the treatment of all gynecologic tumors is great, most of the data to date have been generated in ovarian cancer. Clinical trials of alpha interferon administered intraperitoneally in patients with small volume ovarian cancer have revealed high response rates with acceptable toxicity. The mechanism of the antitumor effect (i.e., direct tumor killing vs. indirect boosting host immune response) has not yet been determined. Clinical trials of intraperitoneal lymphokine‐activated killer (LAK) cells plus recombinant interleukin‐2 have also been started based upon significant antitumor effects noted in xenogeneic systems. The finding that the peritoneal fluid of interferon‐treated patients is rich with monocytes and macrophages has led to the development of a clinical trial using intraperitoneal human monocytes activated with recombinant gamma interferon along with gamma interferon. Monoclonal antibodies have already made a significant impact on the diagnosis of ovarian cancer, and are being brought to clinical trial as therapeutic agents. The OC‐125 antigen is shed by ovarian tumor cells and its elevation in the serum of patients with undiagnosed pelvic masses is highly predictive for ovarian neoplasia. Furthermore, its persistence in the serum of patients with ovarian cancer during chemotherapy is nearly always associated with persistent disease. A number of monoclonal antibodies specific for ovarian cancer have been developed. Radiolabeled antibodies administered intralymphatically and intraperitoneally may be able to demonstrate the presence of tumor reliably enough to save some patients from second‐look laparotomy. In addition, clinical trials are underway using immunotoxins, antitumor antibodies conjugated to potent plant or bacterial toxins that are effective at killing cells with amazing efficiency. Antibodies conjugated to alpha‐emitting radioisotopes like astatine‐211 or to radioisotopes emitting gamma or beta waves or Auger electrons are candidates for clinical trial. There is also some interest in attempting to improve the therapeutic index by using antibodies conjugated to cytotoxic chemotherapeutic agents. It is also possible that an antibody would not need to be attached to another effector molecule if it were directed against a growth‐factor receptor or some other physiologically important target on the tumor cells. The integration of these approaches with more conventional treatment may be associated with an increase in complete remission rate and long‐term survival. Yet another biologic agent of particular interest in gynecologic neoplasms is Mullerian inhibiting substance (MIS). Since the genitourinary tr...

show abstract

Intraperitoneal immunotherapy of epithelial ovarian carcinoma with Corynebacterium parvum

Cited by 39 publications

References 5 publications

Immunotherapy trials: Current status and future directions with special emphasis on biologic drugs

Immunotherapy trials: Current status and future directions with special emphasis on biologic drugs

Biological response modifiers in the management of patients with breast cancer

Biologic therapy for the treatment of malignant common epithelial tumors of the ovary

Contact Info

Product

Resources

About